Kane Biotech Inc (V:KNE) is taking a unique approach to addressing human and animal health by developing technology to break up biofilms, the glue-like substance secreted by microorganisms that prevent their removal. Biofilms are implicated in a range of health concerns from periodontal disease, medical device-associated infections, hospital-acquired infections and food safety. As the first commercial use of its technology, the company has launched a series of products to prevent tartar build-up in companion animals.
Biofilms: Microbes’ first line of defence
Biofilms are the mixtures of proteins and carbohydrates secreted by bacteria and fungi that act as a glue to adhere them to a surface and provide a barrier against antimicrobials, disinfectants, and the immune system. These biofilms may form on living tissue such as the teeth and skin, or on hard surfaces in hospitals and food processing facilities, leading to the transmission of pathogenic species. Kane’s goal is to develop a suite of products targeting these niches in animal and human health, and to out-license these products.
Agreement with Dechra for veterinary products
Kane recently licensed the technology for its animal health products to Dechra, a worldwide manufacturer of veterinary products, for marketing in North American vet channels (Kane separately markets its own dental products in specialty stores). Kane received $500k on signing and is entitled to $2m in milestones plus royalties (subject to minimums). The dental health product, Vetradent, was launched in the US in October 2017, and an ear drop is targeted for H218.
To read the entire report Please click on the pdf File Below: